Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13611934 | 0.87 | KMO (0.61) | DYRK1AKMONEK1KMT2A | |
| SCHEMBL13743373 | 0.85 | CYP2C19 (0.46) | ABL1LMNADYRK1AKMOHDAC8 | |
| SCHEMBL13611932 | 0.84 | AURKA (0.53) | LMNAHDAC8 | |
| SCHEMBL13701655 | 0.83 | ABL1 (0.50) | KAT6AABL1CYP2C19 | |
| SCHEMBL13701695 | 0.83 | HDAC8 (0.64) | KAT6ALMNAKMOHDAC8 | |
| SCHEMBL13701654 | 0.81 | RXRA (0.59) | LMNAKMOHDAC8CYP2C19KMT2A | |
| SCHEMBL13701631 | 0.81 | HDAC8 (0.54) | LMNAHDAC8CYP2C19KMT2A | |
| SCHEMBL13485770 | 0.81 | HDAC8 (0.67) | KAT6AABL1KMOHDAC8CNR1 | |
| SCHEMBL17773164 | 0.80 | ABL1 (0.48) | KAT6AABL1KMONEK1CTSL | |
| SCHEMBL13701672 | 0.80 | PLAU (0.48) | LMNAHDAC8CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | KAT6A 3567/4885ABL1 4720/4885LMNA 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.